This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALBO Albireo Pharma (ALBO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Albireo Pharma Stock (NASDAQ:ALBO) 30 days 90 days 365 days Advanced Chart Get Albireo Pharma alerts:Sign Up Key Stats Today's Range$43.99▼$44.9050-Day Range$43.50▼$44.9552-Week Range$16.02▼$45.23Volume1.24 million shsAverage Volume704,539 shsMarket Capitalization$913.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. Read More Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Stock News HeadlinesAlbireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and ReliabilityMay 6, 2024 | businesswire.comProspect Park II in Fort LauderdaleJanuary 19, 2024 | bizjournals.com[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.July 16 at 2:00 AM | Crypto Swap Profits (Ad)ALBO Historical DataOctober 1, 2023 | investing.comIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioMarch 4, 2023 | finanznachrichten.deALBO Albireo Pharma, Inc.February 25, 2023 | seekingalpha.comAlbireo Pharma, Inc. (ALBO)February 18, 2023 | uk.finance.yahoo.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | marketwatch.comSee More Headlines ALBO Stock Analysis - Frequently Asked Questions How were Albireo Pharma's earnings last quarter? Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN). Company Calendar Last Earnings11/04/2021Today7/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALBO CIK1322505 Webwww.albireopharma.com Phone(857) 254-5555Fax203-796-5001Employees130Year Founded2003Profitability EPS (Trailing Twelve Months)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.03 million Net Margins-228.51% Pretax Margin-235.11% Return on Equity-97.13% Return on Assets-46.89% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.23 Sales & Book Value Annual Sales$40.58 million Price / Sales22.52 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book4.85Miscellaneous Outstanding Shares20,700,000Free Float19,273,000Market Cap$913.91 million OptionableOptionable Beta1.03 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ALBO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Albireo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBO Stock Alerts